Solid Biosciences (SLDB) Operating Leases (2019 - 2024)
Solid Biosciences (SLDB) has disclosed Operating Leases for 6 consecutive years, with $21.6 million as the latest value for Q3 2024.
- Quarterly Operating Leases fell 6.67% to $21.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $21.6 million through Sep 2024, down 6.67% year-over-year, with the annual reading at $22.7 million for FY2023, 6.47% down from the prior year.
- Operating Leases hit $21.6 million in Q3 2024 for Solid Biosciences, down from $22.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $24.5 million in Q2 2022 to a low of $70000.0 in Q1 2022.
- Historically, Operating Leases has averaged $13.1 million across 5 years, with a median of $21.6 million in 2024.
- Biggest five-year swings in Operating Leases: tumbled 96.46% in 2022 and later skyrocketed 34060.0% in 2023.
- Year by year, Operating Leases stood at $2.4 million in 2020, then tumbled by 88.63% to $275000.0 in 2021, then surged by 8728.73% to $24.3 million in 2022, then fell by 6.47% to $22.7 million in 2023, then fell by 4.69% to $21.6 million in 2024.
- Business Quant data shows Operating Leases for SLDB at $21.6 million in Q3 2024, $22.1 million in Q2 2024, and $22.5 million in Q1 2024.